Total Payments
$356,192
2024 Payments
$164,824
Companies
32
Transactions
481
Medicare Patients
9,099
Medicare Billing
$3.6M
Payment Breakdown by Category
Other$203,363 (57.1%)
Consulting$102,026 (28.6%)
Travel$30,697 (8.6%)
Food & Beverage$17,084 (4.8%)
Research$3,022 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $193,038 | 58 | 54.2% |
| Consulting Fee | $102,026 | 43 | 28.6% |
| Travel and Lodging | $30,697 | 105 | 8.6% |
| Food and Beverage | $17,084 | 267 | 4.8% |
| Honoraria | $10,325 | 5 | 2.9% |
| Unspecified | $3,022 | 3 | 0.8% |
Payments by Type
General
$353,170
478 transactions
Research
$3,022
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $121,453 | 134 | $0 (2024) |
| Genentech USA, Inc. | $73,368 | 66 | $0 (2024) |
| Astellas Pharma US Inc | $48,018 | 40 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $37,512 | 34 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $28,909 | 45 | $0 (2024) |
| ABBVIE INC. | $9,437 | 19 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $9,003 | 14 | $0 (2021) |
| Coherus Biosciences Inc. | $6,336 | 7 | $0 (2023) |
| EyePoint Pharmaceuticals US, Inc. | $5,238 | 9 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $4,810 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164,824 | 173 | Regeneron Healthcare Solutions, Inc. ($80,010) |
| 2023 | $127,728 | 143 | Regeneron Healthcare Solutions, Inc. ($29,958) |
| 2022 | $45,072 | 80 | Genentech USA, Inc. ($19,882) |
| 2021 | $11,506 | 25 | Bausch & Lomb, a division of Bausch Health US, LLC ($9,003) |
| 2020 | $100.84 | 5 | Allergan, Inc. ($60.48) |
| 2019 | $865.02 | 10 | Alcon Vision LLC ($263.43) |
| 2018 | $3,257 | 20 | Alcon Research Ltd ($1,129) |
| 2017 | $2,838 | 25 | Valeant Pharmaceuticals North America LLC ($1,566) |
All Payment Transactions
481 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Honoraria | Cash or cash equivalent | $1,275.00 | General |
| Category: treatment of diabetic macular edema in patients who have been previously treated with corticosteroid | ||||||
| 12/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | Cash or cash equivalent | $56.08 | General |
| Category: Ophthalmology | ||||||
| 12/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $21.62 | General |
| Category: Ophthalmology | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $3,290.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $32.69 | General |
| Category: Ophthalmology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $10.45 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $133.87 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,530.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/05/2024 | Notal Vision, Inc. | Foresee Home (Device) | Food and Beverage | In-kind items and services | $14.99 | General |
| Category: Ophthalmology | ||||||
| 12/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,904.50 | General |
| Category: Ophthalmology | ||||||
| 11/29/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $38.60 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/29/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $36.12 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/29/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $28.65 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/29/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | Cash or cash equivalent | $4.32 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/21/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,640.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $734.38 | General |
| Category: Ophthalmology | ||||||
| 11/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Travel and Lodging | In-kind items and services | $316.96 | General |
| Category: Ophthalmology | ||||||
| 11/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $110.42 | General |
| Category: Ophthalmology | ||||||
| 11/18/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.62 | General |
| Category: Ophthalmology | ||||||
| 11/15/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $462.50 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $2,977 | 2 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $44.88 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 2,006 | 19,907 | $3.7M | $1.1M |
| 2022 | 15 | 1,451 | 3,096 | $1.8M | $577,623 |
| 2021 | 14 | 2,276 | 4,386 | $1.9M | $734,127 |
| 2020 | 19 | 3,366 | 7,375 | $2.4M | $1.2M |
Total Patients
9,099
Total Services
34,764
Medicare Billing
$3.6M
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 65 | 15,720 | $1.6M | $456,757 | 29.1% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 88 | 564 | $1.1M | $391,994 | 34.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 173 | 576 | $335,750 | $52,189 | 15.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 19 | 285 | $285,000 | $51,453 | 18.1% |
| 92134 | Imaging of retina | Office | 2023 | 466 | 1,101 | $72,155 | $31,249 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 299 | $60,024 | $27,517 | 45.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 211 | 310 | $62,931 | $26,549 | 42.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 126 | 126 | $31,764 | $14,335 | 45.1% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 123 | 123 | $28,485 | $12,206 | 42.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 101 | 139 | $20,914 | $9,445 | 45.2% |
| 92250 | Photography of the retina | Office | 2023 | 201 | 271 | $26,918 | $6,933 | 25.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 57 | 61 | $12,332 | $6,123 | 49.7% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 18 | 23 | $32,200 | $4,276 | 13.3% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 95 | 173 | $8,650 | $2,993 | 34.6% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 12 | 27 | $13,139 | $1,733 | 13.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 22 | 45 | $6,750 | $1,654 | 24.5% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 46 | 52 | $2,072 | $565.41 | 27.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,080 | $507.18 | 47.0% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 74 | 512 | $1.0M | $368,339 | 36.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 21 | 345 | $345,000 | $77,571 | 22.5% |
| 67028 | Injection of drug into eye | Office | 2022 | 118 | 336 | $200,225 | $31,841 | 15.9% |
| 92134 | Imaging of retina | Office | 2022 | 320 | 671 | $44,170 | $19,654 | 44.5% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 135 | 205 | $41,637 | $18,947 | 45.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 162 | $32,400 | $15,871 | 49.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 104 | 104 | $26,088 | $11,781 | 45.2% |
About Dr. Priya Vakharia, MD
Dr. Priya Vakharia, MD is a Retina Specialist healthcare provider based in Palm Harbor, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/25/2013. The National Provider Identifier (NPI) number assigned to this provider is 1215279500.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priya Vakharia, MD has received a total of $356,192 in payments from pharmaceutical and medical device companies, with $164,824 received in 2024. These payments were reported across 481 transactions from 32 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($193,038).
As a Medicare-enrolled provider, Vakharia has provided services to 9,099 Medicare beneficiaries, totaling 34,764 services with total Medicare billing of $3.6M. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Palm Harbor, FL
- Active Since 03/25/2013
- Last Updated 11/11/2021
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1215279500
Products in Payments
- EYLEA HD (Biological) $84,515
- Vabysmo (Drug) $47,117
- Izervay (Drug) $41,331
- EYLEA (Biological) $40,770
- Syfovre (Drug) $31,246
- VABYSMO (Drug) $19,800
- STELLARIS (Device) $11,619
- STELLARIS ELITE (Device) $10,413
- Stellaris (Device) $8,748
- Cimerli (Biological) $6,336
- OZURDEX (Drug) $4,925
- MIEBO (Drug) $4,800
- ILUVIEN (Drug) $4,103
- Susvimo (Drug) $3,330
- EYP-1901 (Drug) $3,062
- Lucentis (Biological) $2,242
- EYP-1901 $1,851
- STELLARIS PC (Device) $1,566
- Constellation (Device) $727.82
- RTH258A (Drug) $443.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.